A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07644286 by Tao Zhang, with a registry enrolment figure of 48 participants, started 2025-12-01 and due to reach its primary completion in 2027-01-25. Interventions recorded: Pirfenidone in combination with a PD-1 inhibitor; hypofractionated radiotherapy. Conditions listed: Colorectal Cancer (CRC). Primary outcome: Progression Free Survival（PFS）. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed, unresectable locally advanced or metastatic pMMR/MSS colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.